title: Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients.
abstract: OBJECTIVE
  A minority of cancer survivors develops long-term postsurgical neuropathic pain. Based on evidence that capsaicin, the pungent ingredient in hot chili peppers, might be useful for treating neuropathic pain, we developed the present clinical trial.
  
  
  METHODS
  Ninety-nine assessable patients with postsurgical neuropathic pain were entered onto this study. After stratification, patients were to receive 8 weeks of a 0.075% capsaicin cream followed by 8 weeks of an identical-appearing placebo cream, or vice versa. A capsaicin/placebo cream was to be applied to the painful site four times daily. Treatment evaluation was performed by patient-completed weekly questionnaires.
  
  
  RESULTS
  During the first 8-week study period, the capsaicin-cream arm was associated with substantially more skin burning, skin redness, and coughing (P < .0001 for each). Nonetheless, treatment was stopped for patient refusal or toxicity just as often while patients were receiving the placebo as compared with the capsaicin. The capsaicin cream arm had substantially more pain relief (P = .01) after the first 8 weeks, with an average pain reduction of 53% versus 17%. On completion of the 16-week study period, patients were asked which treatment period was most beneficial. Of the responding patients, 60% chose the capsaicin arm, 18% chose the placebo arm, and 22% chose neither (P = .001).
  
  
  CONCLUSIONS
  A topical capsaicin cream decreases postsurgical neuropathic pain and, despite some toxicities, is preferred by patients over a placebo by a three-to-one margin among those expressing a preference.
authors.affiliation: Geisinger Clinical Oncology Program, Danville, PA, USA.
authors.forename: N
authors.initials: N
authors.lastname: Ellison
authors.forename: C L
authors.initials: CL
authors.lastname: Loprinzi
authors.forename: J
authors.initials: J
authors.lastname: Kugler
authors.forename: A K
authors.initials: AK
authors.lastname: Hatfield
authors.forename: A
authors.initials: A
authors.lastname: Miser
authors.forename: J A
authors.initials: JA
authors.lastname: Sloan
authors.forename: D B
authors.initials: DB
authors.lastname: Wender
authors.forename: K M
authors.initials: KM
authors.lastname: Rowland
authors.forename: R
authors.initials: R
authors.lastname: Molina
authors.forename: T L
authors.initials: TL
authors.lastname: Cascino
authors.forename: A M
authors.initials: AM
authors.lastname: Vukov
authors.forename: H S
authors.initials: HS
authors.lastname: Dhaliwal
authors.forename: C
authors.initials: C
authors.lastname: Ghosh
mesh_terms: D000287:Administration, Topical; D000368:Aged; D002211:Capsaicin / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000601:surgery*; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology; D009824:Ointments; D010147:Pain Measurement; D010149:Postoperative Pain / Q000188:drug therapy*
chemical_list: D009824:Ointments; D002211:Capsaicin